Allakos
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
825 Industrial Rd Ste 500, San Carlos, C...Phone Number
(650) 597-5002Website
www.allakos.comRevenue
$27.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
2
1
1
About Allakos
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Explore more
Allakos Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Allakos your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Allakos launches new products
Funding: Get notified immidiatlly once Allakos has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Allakos had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Allakos
Check out if Allakos is spiking on competitors!
Check if Allakos has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Allakos recently announced quarterly report
Website visits: Recent activity has been detected on your website
Allakos, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Allakos as Masked Content
Find more new buyers
Compare Similar Companies to Allakos
Compare insights from companies similar to Allakos, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Allakos is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Allakos is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Allakos.
Allakos financials insights
Gather financial insights about Allakos, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$42M
2017
Series B
$100M
2018
Stock Offering
$134.4M
Allakos Tech Stack
A closer look at the technologies used by Allakos
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Person-Based
Person-Based
Allakos News & Media
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Allakos will receive $0.33 in cash per each share of Allakos common stock. AAllakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC ( “Concentra”) will acquire Allakos for $0.33 in cash per share of Allakos common stock (“Allakos Common Stock”).Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024.Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Allakos
Sign Up For FreeTo access detailed company insights
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urtic... Read More
